MOR Ok, finally a legit play. We had to find one, right? "No, often not". OK, lol
$8.37 +1.32 (+18.72%)
As of Dec-11-202310:38:39 AM ET
The News
MorphoSys Presented Comprehensive Results From The Phase 3 MANIFEST-2 Study Investigating Pelabresib At 65th American Society Of Hematology Annual Meeting
BENZINGA 1:52 AM ET Dec-11-2023
Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib
Showed a strong positive trend in reducing symptom burden and a twofold increase in patients achieving both SVR35 and TSS50 versus placebo plus ruxolitinib
Improved measures of anemia, including higher hemoglobin response rates, fewer patients requiring transfusions and fewer anemia adverse events versus placebo plus ruxolitinib
Improved bone marrow fibrosis by at least one grade in more patients versus placebo plus ruxolitinib
Demonstrated safety results consistent with prior clinical trials, with fewer grade ≥3 adverse events compared with placebo plus ruxolitinib
MorphoSys (MOR.NaE) will host an investor event to review findings on Monday, December 11
